Lightpoint’s surgical guidance AI capabilities will complement Telix’s AI programme.
Australia-based Telix Pharmaceuticals has signed an agreement to acquire UK-based Lightpoint Medical along with its SENSEI radio-guided surgery business.
The purchase price consists of an upfront equity payment of A$29m ($20m) and a further earn-out payment of A$22m ($15m) in cash or equity, after attaining certain milestones linked to the ongoing development and commercialisation of the SENSEI probe.
Designed for intracavitary use, SENSEI is an ultra-miniature robotic gamma probe that facilitates intra-operative cancer detection in real time to offer radiopharmaceutical-based surgical guidance (radio-guided surgery).